Fecal Microbiome Transplantation for Recurrent CDI: Treatment Efficacy and Safety with Oral Capsules.

IF 2
Tadas Urbonas, Dalius Petrauskas, Vytautas Kiudelis, Laimas Jonaitis, Jurgita Skieceviciene, Rolandas Gedgaudas, Edita Kiudeliene, Irena Valantiene, Romanas Zykus, Greta Varkalaite, Ruta Inciuraite, Elzbieta Trapenske, Ugne Kulokiene, Paulius Jonaitis, Rima Ramonaite, Justina Velickiene, Aida Zvirbliene, Egidijus Morkunas, Irma Kuliaviene, Jolanta Sumskiene, Kestutis Adamonis, Andrius Macas, Kristina Kupcinskiene, Laura Lukosiene, Dainius Janciauskas, Lina Poskiene, Astra Vitkauskiene, Gianluca Ianiro, Antonio Gasbarrini, Gediminas Kiudelis, Juozas Kupcinskas
{"title":"Fecal Microbiome Transplantation for Recurrent CDI: Treatment Efficacy and Safety with Oral Capsules.","authors":"Tadas Urbonas, Dalius Petrauskas, Vytautas Kiudelis, Laimas Jonaitis, Jurgita Skieceviciene, Rolandas Gedgaudas, Edita Kiudeliene, Irena Valantiene, Romanas Zykus, Greta Varkalaite, Ruta Inciuraite, Elzbieta Trapenske, Ugne Kulokiene, Paulius Jonaitis, Rima Ramonaite, Justina Velickiene, Aida Zvirbliene, Egidijus Morkunas, Irma Kuliaviene, Jolanta Sumskiene, Kestutis Adamonis, Andrius Macas, Kristina Kupcinskiene, Laura Lukosiene, Dainius Janciauskas, Lina Poskiene, Astra Vitkauskiene, Gianluca Ianiro, Antonio Gasbarrini, Gediminas Kiudelis, Juozas Kupcinskas","doi":"10.15403/jgld-5990","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Fecal microbiota transplantation is an effective treatment method for recurrent Clostridioides difficile infection. Widely used enteric tube and colonoscopy methods demonstrate excellent efficacy and safety results. Recent data suggest that new fecal microbiota transplantation methods using oral capsules may provide a less invasive approach. In this study, we aimed to compare primary fecal microbiota transplantation efficacy as well as short- and long-term safety of two different administration routes: oral capsules and enteric tube.</p><p><strong>Methods: </strong>This retrospective study included 60 consecutive patients who underwent fecal microbiota transplantation for recurrent Clostridioides difficile infection. Thirty participants received 50 oral capsules containing frozen material for a single day and 30 patients received fecal microbiota transplantation via nasoenteric tube. All patients received standard treatment with oral vancomycin 500 mg q.i.d. for at least five days before the procedure. After intervention, patients were followed up for at least six months. Data on Clostridioides difficile infection recurrences and health status were collected and analyzed.</p><p><strong>Results: </strong>The oral capsules group consisted of 30 patients. Among them, 22 (73.3%) participants experienced resolution of symptoms after a single fecal microbiota transplantation, while eight (26.7%) patients developed recurrent diarrhea within eight weeks. The other 30 patients received treatment via nasoenteric tube. Among them, 24 (80%) patients were cured after a single fecal microbiota transplantation, while six (20%) experienced recurrent disease within eight weeks. The primary efficacy did not show significant differences between the two groups (p=0.85). Throughout the follow-up period, no serious adverse events or fecal microbiota transplantation related deaths were reported in both groups.</p><p><strong>Conclusions: </strong>Fecal microbiota transplantation with frozen oral capsules is a safe, less invasive method with comparable efficacy to nasoenteric administration route.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 2","pages":"199-204"},"PeriodicalIF":2.0000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gastrointestinal and liver diseases : JGLD","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15403/jgld-5990","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims: Fecal microbiota transplantation is an effective treatment method for recurrent Clostridioides difficile infection. Widely used enteric tube and colonoscopy methods demonstrate excellent efficacy and safety results. Recent data suggest that new fecal microbiota transplantation methods using oral capsules may provide a less invasive approach. In this study, we aimed to compare primary fecal microbiota transplantation efficacy as well as short- and long-term safety of two different administration routes: oral capsules and enteric tube.

Methods: This retrospective study included 60 consecutive patients who underwent fecal microbiota transplantation for recurrent Clostridioides difficile infection. Thirty participants received 50 oral capsules containing frozen material for a single day and 30 patients received fecal microbiota transplantation via nasoenteric tube. All patients received standard treatment with oral vancomycin 500 mg q.i.d. for at least five days before the procedure. After intervention, patients were followed up for at least six months. Data on Clostridioides difficile infection recurrences and health status were collected and analyzed.

Results: The oral capsules group consisted of 30 patients. Among them, 22 (73.3%) participants experienced resolution of symptoms after a single fecal microbiota transplantation, while eight (26.7%) patients developed recurrent diarrhea within eight weeks. The other 30 patients received treatment via nasoenteric tube. Among them, 24 (80%) patients were cured after a single fecal microbiota transplantation, while six (20%) experienced recurrent disease within eight weeks. The primary efficacy did not show significant differences between the two groups (p=0.85). Throughout the follow-up period, no serious adverse events or fecal microbiota transplantation related deaths were reported in both groups.

Conclusions: Fecal microbiota transplantation with frozen oral capsules is a safe, less invasive method with comparable efficacy to nasoenteric administration route.

粪便微生物组移植治疗复发性CDI:口服胶囊治疗的疗效和安全性。
背景与目的:粪便菌群移植是治疗复发性难辨梭菌感染的有效方法。肠管和结肠镜检查方法广泛应用,具有良好的疗效和安全性。最近的数据表明,使用口服胶囊的新的粪便微生物群移植方法可能提供一种侵入性较小的方法。在本研究中,我们旨在比较口服胶囊和肠管两种不同给药途径的初级粪便微生物群移植疗效以及短期和长期安全性。方法:本回顾性研究包括60例连续接受粪便菌群移植治疗复发性艰难梭菌感染的患者。30名参与者接受50粒含冷冻材料的口服胶囊,为期一天,30名患者通过鼻肠管接受粪便微生物群移植。所有患者在手术前至少5天接受口服万古霉素500毫克/次的标准治疗。干预后,对患者进行了至少六个月的随访。收集并分析艰难梭菌感染复发及健康状况。结果:口服胶囊组30例。其中,22例(73.3%)患者在单次粪便菌群移植后症状缓解,8例(26.7%)患者在8周内复发腹泻。其余30例患者经鼻肠管治疗。其中24例(80%)患者在单次粪便菌群移植后治愈,6例(20%)患者在8周内复发。两组的主要疗效差异无统计学意义(p=0.85)。在整个随访期间,两组均未报告严重不良事件或粪便菌群移植相关死亡。结论:冷冻口服胶囊粪便菌群移植是一种安全、微创的方法,与鼻肠给药方式疗效相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信